Company Profile

Hypogen Inc
Profile last edited on: 7/22/09      CAGE: 47HP9      UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1841 Fendell Ave
Charlottesville, VA 22903
   (434) 924-5151
Location: Single
Congr. District: 05
County: Charlottesville city

Public Profile

Hypogen, Inc., is a biopharmaceutical company focused on the development of novel diagnostic tests and new therapeutics for essential hypertension. Hypertension is the world’s most prevalent disease, affecting more than 25 percent of the population, and continues to be a leading cause of morbidity and mortality. Hypogen Inc. is developing a new generation of drugs that, for the first time, would treat high blood pressure at the genetic level. Hypogen is also creating a simple diagnostic blood test that can determine if a person has specific genetic defects putting them at a significant risk of developing high blood pressure

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2004 1 NIH $153,537
Project Title: Genetic Diagnostic Test for Essential Hypertension

Key People / Management

  Robin A Felder

Company News

There are no news available.